化工社化工社 化学情報印刷レポート · 研究参考用
5-アミノレブリン酸塩酸塩
5-アミノレブリン酸塩酸塩 · 4-カルボキシ-2-オキソブチルアミン·塩酸塩 · 4-カルボキシ-2-オキソブチルアンモニウム=クロリド · 5-アミノ-4-オキソペンタン酸=塩酸塩 · 5-アミノ-4-オキソペンタン酸·塩酸塩 · 5‐アミノレブリン酸塩酸塩 · アミノレブリン酸HCL · 5-アミノ-4-オキソペンタン酸塩酸塩
識別子と物理属性
| CAS No. | 5451-09-2 |
|---|---|
| 分子式 | C5H10ClNO3 |
| 平均分子量 | 167.59 g/mol |
| 単同位体質量 | 167.03492086 g/mol |
| SMILES | Cl.NCC(=O)CCC(=O)O |
| InChIKey | ZLHFONARZHCSET-UHFFFAOYSA-N |
| PubChem CID | 123608 |
| ChEMBL | CHEMBL1200582 |
| ChEBI | CHEBI:132969 |
| DTXSID | DTXSID5045914 |
| 現地名 | 5-アミノレブリン酸塩酸塩 |
化学・物理的性質
| 極性表面積 | 80.4 |
|---|---|
| 水素結合供与体数 | 3 |
| 水素結合受容体数 | 4 |
| 回転可能結合数 | 4 |
| 重原子数 | 10 |
| 形式電荷 | 0 |
| 複雑度 | 121 |
| Human Drugs | Breast FeedingLactationMilk, HumanDermatologic AgentsPhotosensitizing AgentsFDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| 融点 | ~150 °C (dec.) |
| 引火点 | 155-157°C |
| 貯蔵条件 | -20°C |
| 溶解度 | H2O: 50 mg/mLジメチルスルホキシド、メタノール、水に可溶。 |
| 外観・状態 | 粉 |
| 色 | 白色～淡黄色 |
| pH | pH (10g/l, 25℃) : 2.5～3.0 |
| Decomposition | 155-157 ºC |
| Merck | 14,446 |
| BRN | 3690651 |
| 安定性 | Hygroscopic |
| 化粧品成分の機能 | 肌を保護する抗菌剤ヘアコンディショニング皮脂抑制 |
| InChI | 1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)1H |
| InChIKey | ZLHFONARZHCSET-UHFFFAOYSA-N |
| SMILES | Cl[H].NCC(=O)CCC(O)=O |
| CAS データベース | 5451-09-2(CAS DataBase Reference) |
化学的特性
white to pale yellow crystals or
安全性と法規制
| 規制情報 | Pentanoic acid, 5-amino-4-oxo-, hydrochloride: Does not have an individual approval but may be used under an appropriate group standard |
|---|---|
| その他の安全情報 | IMAP assessments - Pentanoic acid, 5-amino-4-oxo-, hydrochloride: Environment tier I assessment |
| 暴露経路 | Oral bioavailability is 50-60%. |
| 毒性の概要 | According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT). |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| F | 3-8-10 |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | OI1640000 |
| 税関コード | 29224999 |
| 危険文句（R） | 36/37/38-66-20/21/22-36/38 |
| 化審法 | 新規公示化学物質（2011年3月31日以前届出） |
| 危険表示 | Xi,Xn |
| hazard_note | Irritant |
| 安全措置（S） | 26-36/37-37/39-36 |
| 貯蔵分類 | 11 - Combustible Solids |
用途
使用
5-Aminolevulinic acid hydrochloride finds an important role as a precursor in the synthesis of tetrapyrroles such as chlorophyll and heme. It is widely utilized in photodynamic therapy of diseases namely, Pagets disease and human papillomavirus (HPV) infection-associated cervical condylomata acuminata.
製法・合成法
純化方法
Dry ALA-HCl in a vacuum desiccator over P2O5 overnight, then crystallise it by dissolving it in cold EtOH and adding dry Et2O. Also crystallis